MDKI, a novel receptor tyrosine kinase

Details MDKI, a novel receptor tyrosine kinase MDKI, a novel receptor tyrosine kinase

1995-01-03

2001-10-09

Ungar, Susan (Department: 1642)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S024310, C435S320100, C435S252300, C435S069100

Reexamination Certificate

active

06300482

ABSTRACT:

FIELD OF THE INVENTION
The present invention relates generally to the field of cellular signal transduction and more specifically to the diagnosis and treatment of various diseases and conditions associated with abnormal cellular signal transduction pathways.
BACKGROUND OF THE INVENTION
The present invention concerns methods for diagnosis and treatment of disorders characterized by abnormal cellular signal transduction. The following is a discussion of relevant art, none of which is admitted to be prior art to the invention.
Cellular signal transduction is a fundamental mechanism whereby external stimuli that regulate diverse cellular processes are relayed to the interior of cells. One of the key biochemical mechanisms of signal transduction involves the reversible phosphorylation of tyrosine residues on proteins. The phosphorylation state of a protein is modified through the reciprocal actions of tyrosine kinases (TKs) and tyrosine phosphatases (TPs).
Receptor tyrosine kinases (RTKs) belong to a family of transmembrane proteins and have been implicated in cellular signaling pathways. The predominant biological activity of some RTKs is the stimulation of cell growth and proliferation, while other RTKs are involved in arresting growth and promoting differentiation. In some instances, a single tyrosine kinase can inhibit, or stimulate, cell proliferation depending on the cellular environment in which it is expressed.
RTKs are composed of at least three domains: an extracellular ligand binding domain, a transmembrane domain and a cytoplasmic catalytic domain that can phosphorylate tyrosine residues. Ligand binding to membrane-bound receptors induces the formation of receptor dimers and allosteric changes that activate the intracellular kinase domains and result in the self-phosphorylation (autophosphorylation and/or transphosphorylation) of the receptor on tyrosine residues. Their intrinsic tyrosine kinase is activated upon ligand binding, thereby initiating a complex signal transduction pathway that begins with receptor autophosphorylation and culminates in the tyrosine phosphorylation of a variety of cellular substrates and ultimately in the initiation of nuclear events necessary for the overall cell response. Individual phosphotyrosine residues of the cytoplasmic domains of receptors may serve as specific binding sites that interact with a host of cytoplasmic signaling molecules, thereby activating various signal transduction pathways.
The intracellular, cytoplasmic, non-receptor protein tyrosine kinases do not contain a hydrophobic transmembrane domain or an extracellular domain and share non-catalytic domains in addition to sharing their catalytic kinase domains. Such non-catalytic domains include the SH2 domains (SRC homology domain 2) and SH3 domains (SRC homology domain 3). The non-catalytic domains are thought to be important in the regulation of protein-protein interactions during signal transduction.
A central feature of signal transduction (for reviews, see Posada and Cooper,
Mol. Biol. Cell
3:583-392, 1992; Hardie,
Symp. Soc. Exp. Biol.
44:241-255, 1990), is the reversible phosphorylation of certain proteins. Receptor phosphorylation stimulates a physical association of the activated receptor with target molecules. Some of the target molecules such as phospholipase C
&ggr;
are in turn phosphorylated and activated. Such phosphorylation transmits a signal to the cytoplasm. Other target molecules are not phosphorylated, but assist in signal transmission by acting as adapter molecules for secondary signal transducer proteins. For example, receptor phosphorylation and the subsequent allosteric changes in the receptor recruit the Grb-2/SOS complex to the catalytic domain of the receptor where its proximity to the membrane allows it to activate ras.
The secondary signal transducer molecules generated by activated receptors result in a signal cascade that regulates cell functions such as cell division or differentiation. Reviews describing intracellular signal transduction include Aaronson,
Science,
254:1146-1153, 1991; Schlessinger,
Trends Biochem. Sci.,
13:443-447, 1988; and Ullrich and Schlessinger,
Cell,
61:203-212, 1990.
RTKs are important regulators of developmental processes, as reflected by the high level of tyrosine phosphorylation in the early mouse embryo, which decreases with progressing development and is low in adult animal tissues (Pasquale and Singer,
Proc. Natl. Acad. Sci. USA
88:5449-5453, 1989). For example, the mouse c-kit proto-oncogene plays a key role in the migrational behavior of specific cell types in mouse development (Chabot et al.,
Nature
335:88-89, 1988; Geissler et al.,
Cell
55:185-192, 1988; Nocka et al.,
Genes Dev.
3:816-826, 1989).
Disruption of the platelet-derived growth factor receptor &agr; (PDGF-R&agr;) gene is responsible for the mouse patch mutation, which is characterized by prominent anatomical abnormalities in homozygotes (Stephenson et al.,
Proc. Natl. Acad. Sci. USA
88:6-10, 1991). Moreover, Flk-1, the cognate receptor for the vascular endothelial growth factor (VEGF), was shown to be a major regulator of vasculogenesis and angiogenesis (Millauer et al.,
Cell
72:835-846, 1993). Finally, in Drosophila, the RTK sevenless has a well established function in the control of photoreceptor cell fate (Basler and Hafen,
Science
243:931-934, 1989), as does the RTK torso in the formation of terminal structures of Drosophila larva (Sprenger et al.,
Nature
338:478-483, 1989).
Among adult tissues, the brain contains the highest level of protein kinase activity, comparable to that found in embryonic tissues (Maher, P. A.,
J. Cell. Biol.
112:955-963, 1991). Members of the trk family of RTKs have well documented roles in promoting the differentiation and survival of diverse groups of neurons of the central and peripheral nervous systems (reviewed in Raffioni et al.,
Annu. Rev. Biochem.
62:823-850, 1993). The eck/eph RTK subfamily (Hirai et al.,
Science
238:1717-1720, 1987) currently comprises the largest subgroup of RTKs (Sajjadi and Pasquale,
Oncogene
8:1807-1813, 1993), with most members being expressed in the developing or adult brain.
While RTKs such as eck (Lindberg and Hunter,
Mol. Cell. Biol.
10:6316-6324, 1990), Hek2 (Böhme et al.,
Oncogene
8:2857-2862, 1993), Cek6, Cek9, and Cek10 (Sajjadi and Pasquale,
Oncogene
8:1807-1813, 1993) have been reported to be widely expressed in a variety of tissues, Elk and Cek5 transcripts have been found predominantly in the brain (Letwin et al.,
Oncogene
3:621-627, 1988; Pasquale et al.,
J. Neuroscience
12:3956-3967, 1992).
As first noted by Maisonpierre et al. (Maisonpierre et al.,
Oncogene
8:3277-3288, 1993), there is a subclass of RTKs within the eck/eph family which, while being strongly expressed in the brain, are also found in other tissues, especially during embryogenesis. This subfamily includes Ehk-1, Ehk-2, (Maisonpierre et al.,
Oncogene
8:3277-3288, 1993), Mek4, Cek4, Hek (Sajjadi et al.,
New Biol.
3:769-778, 1991; Wicks et al.,
Proc. Natl. Acad. Sci. USA
89:1611-1615, 1992), eek (Chan and Watt,
Oncogene
6:1057-1061, 1991), Sek (Nieto et al.,
Development
116:1137-1150, 1992; Gilardi-Hebenstreit et al.,
Oncogene
7:2499-2506, 1992), Cek7 and Cek8 (Sajjadi and Pasquale,
Oncogene
8:1807-1813, 1993), whose members are more related to each other than to either of the above-mentioned kinases.
SUMMARY OF THE INVENTION
The present invention relates to MDK1 polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. In particular, this invention relates to methods for diagnosis and treatment of a disorder, most preferably a disorder characterized by an abnormality in a signal transduction pathway, wherein the signal transduction pathway involves the interaction between a MDK1 receptor tyrosine kinase and a MDK1 binding partner.
The present invention is based upon the isolation a

Affiliated with

Also associated with

Rating

MDKI, a novel receptor tyrosine kinase does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with MDKI, a novel receptor tyrosine kinase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and MDKI, a novel receptor tyrosine kinase will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2605225